[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2012003598A - Anticuerpos biespecificos agonistas de receptores de muerte. - Google Patents

Anticuerpos biespecificos agonistas de receptores de muerte.

Info

Publication number
MX2012003598A
MX2012003598A MX2012003598A MX2012003598A MX2012003598A MX 2012003598 A MX2012003598 A MX 2012003598A MX 2012003598 A MX2012003598 A MX 2012003598A MX 2012003598 A MX2012003598 A MX 2012003598A MX 2012003598 A MX2012003598 A MX 2012003598A
Authority
MX
Mexico
Prior art keywords
death receptor
agonistic antibodies
receptor agonistic
bispecific death
bispecific
Prior art date
Application number
MX2012003598A
Other languages
English (en)
Inventor
Pablo Umana
Peter Bruenker
Claudia Ferrara Koller
Ekkehard Moessner
Sandra Grau
Sylvia Herter
Christoph Lampert
Inja Waldhauer
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of MX2012003598A publication Critical patent/MX2012003598A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a anticuerpos biespecíficos que comprenden un primer sitio de unión a antígenos específico para un receptor de muerte y un segundo sitio de unión a antígenos específico para un segundo antígeno, métodos para su producción, composiciones farmacéuticas que contienen los anticuerpos y usos de los mismos.
MX2012003598A 2009-09-29 2010-09-27 Anticuerpos biespecificos agonistas de receptores de muerte. MX2012003598A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09171659 2009-09-29
PCT/EP2010/064209 WO2011039126A1 (en) 2009-09-29 2010-09-27 Bispecific death receptor agonistic antibodies

Publications (1)

Publication Number Publication Date
MX2012003598A true MX2012003598A (es) 2012-04-20

Family

ID=43086853

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003598A MX2012003598A (es) 2009-09-29 2010-09-27 Anticuerpos biespecificos agonistas de receptores de muerte.

Country Status (19)

Country Link
US (1) US9481730B2 (es)
EP (1) EP2483310B1 (es)
JP (1) JP5695059B2 (es)
KR (1) KR101508043B1 (es)
CN (1) CN102574921B (es)
AU (1) AU2010303142B2 (es)
BR (1) BR112012006326A2 (es)
CA (1) CA2773515C (es)
CY (1) CY1115639T1 (es)
DK (1) DK2483310T3 (es)
ES (1) ES2505269T3 (es)
HK (1) HK1169132A1 (es)
HR (1) HRP20141032T1 (es)
IL (1) IL218437A (es)
MX (1) MX2012003598A (es)
PL (1) PL2483310T3 (es)
PT (1) PT2483310E (es)
SI (1) SI2483310T1 (es)
WO (1) WO2011039126A1 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
CN102369215B (zh) * 2009-04-02 2015-01-21 罗切格利卡特公司 包含全长抗体和单链Fab片段的多特异性抗体
EP2417156B1 (en) 2009-04-07 2015-02-11 Roche Glycart AG Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CA2781519A1 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
BR112013003361B8 (pt) 2010-08-13 2022-01-25 Roche Glycart Ag Anticorpo, composição, conjugado de anticorpo,formulação farmacêutica e uso do anticorpo
BR112013001847A2 (pt) 2010-08-24 2016-05-31 Hoffmann La Roche anticorpo biespecífico, método de preparação do anticorpo biespecífico, do anticorpo biespecífico trivalente, métodos e composição farmacêutica
PL2636736T3 (pl) 2010-10-29 2016-09-30 Nowe przeciwciało anty-dr5
EP4303236A3 (en) 2010-11-30 2024-03-20 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
SG10201604160WA (en) 2011-02-10 2016-07-28 Roche Glycart Ag Mutant Interleukin-2 Polypeptides
KR101572338B1 (ko) 2011-02-28 2015-11-26 에프. 호프만-라 로슈 아게 1가 항원 결합 단백질
BR112013019975A2 (pt) 2011-02-28 2017-08-01 Hoffmann La Roche proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
UA115030C2 (uk) 2011-03-02 2017-09-11 Рош Глікарт Аг Антитіло, яке зв'язується зі зв'язаним з мембраною карциноембріональним антигеном (сеа)
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CN104105711B (zh) 2012-02-10 2018-11-30 弗·哈夫曼-拉罗切有限公司 单链抗体及其他异多聚体
AU2013259276B2 (en) 2012-05-10 2018-03-22 Bioatla Llc Multi-specific monoclonal antibodies
KR20150023889A (ko) 2012-06-27 2015-03-05 에프. 호프만-라 로슈 아게 2 개 이상의 상이한 결합 단위를 함유하는 맞춤-제작된 고도로 선별적이고 다중-특이적인 표적화 단위의 선별 및 제조 방법 및 이의 용도
CN104411718B (zh) 2012-06-27 2018-04-24 弗·哈夫曼-拉罗切有限公司 用于制备包含特异性结合靶的至少一种结合实体的抗体Fc区缀合物的方法及其用途
EP2961772A1 (en) * 2013-02-26 2016-01-06 Roche Glycart AG Anti-mcsp antibodies
HUE035865T2 (en) 2013-03-14 2018-05-28 Bristol Myers Squibb Co Combination of DR5 agonist and anti-PD-1 antagonist and methods of use
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
GB201317928D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Molecule
MX2016003593A (es) 2013-10-11 2016-06-02 Hoffmann La Roche Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico.
CN118440206A (zh) * 2014-04-07 2024-08-06 中外制药株式会社 免疫活化抗原结合分子
SG11201609370QA (en) 2014-05-13 2016-12-29 Chugai Pharmaceutical Co Ltd T cell-redirected antigen-binding molecule for cells having immunosuppression function
BR112017006468A2 (pt) * 2014-10-08 2017-12-19 Hoffmann La Roche anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer
WO2016077638A1 (en) * 2014-11-12 2016-05-19 Memorial Sloan Kettering Cancer Center Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof
ES2871045T3 (es) 2014-11-14 2021-10-28 Hoffmann La Roche Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de TNF
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
JP6721590B2 (ja) 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
WO2016103205A1 (en) * 2014-12-23 2016-06-30 Universita' Degli Studi Di Parma Pro-apoptotic anti-ng2/cspg4 antibodies and their uses for disease therapy
SG11201706024YA (en) 2015-01-26 2017-08-30 Macrogenics Inc Multivalent molecules comprising dr5-binding domains
CN104818295A (zh) * 2015-02-03 2015-08-05 武汉友芝友生物制药有限公司 制备和筛选表达双特异性抗体细胞株的方法
CN107207579B (zh) 2015-03-31 2022-02-25 豪夫迈·罗氏有限公司 包含三聚体tnf家族配体的抗原结合分子
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
WO2017055395A1 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
MA43017A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
EP3378488A4 (en) 2015-11-18 2019-10-30 Chugai Seiyaku Kabushiki Kaisha METHOD FOR ENHANCING THE HUMORAL IMMUNE RESPONSE
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
WO2017194597A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
JP7106187B2 (ja) 2016-05-11 2022-07-26 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを保存する方法
ES2909833T3 (es) 2016-05-11 2022-05-10 Cytiva Bioprocess R & D Ab Método de limpieza y/o desinfección de una matriz de separación
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
US11613785B2 (en) 2017-01-09 2023-03-28 Onkosxcel Therapeutics, Llc Predictive and diagnostic methods for prostate cancer
US20200283537A1 (en) * 2017-11-14 2020-09-10 University Of Virginia Patent Foundation Compositions and methods for making and using bispecific antibodies
US20210308243A1 (en) * 2018-08-01 2021-10-07 The Wistar Institute Of Anatomy And Biology Optimized synthetic consensus immunogenic compositions targeting chondroitin sulfate proteoglycan 4 (cspg4)
CR20240246A (es) * 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
US20240052065A1 (en) 2022-07-15 2024-02-15 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
WO2024102962A1 (en) 2022-11-10 2024-05-16 Immuvia Inc Cytotoxic bispecific antibodies binding to dr5 and muc16 and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5580774A (en) * 1989-07-31 1996-12-03 Eli Lilly And Company Chimeric antibodies directed against a human glycoprotein antigen
GB9317423D0 (en) 1993-08-21 1993-10-06 Imp Cancer Res Tech Monoclonal antibodies
DE10034607A1 (de) * 2000-07-20 2002-02-07 Gundram Jung Multispezifisches Reagenz zur selektiven Stimulierung von Zelloberflächenrezeptoren
DE10045591A1 (de) * 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
US20020155109A1 (en) * 2001-04-20 2002-10-24 Lynch David H. Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
CA2560742A1 (en) * 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
CA2587766A1 (en) * 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
CA2593212A1 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Cripto binding molecules
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
BR112013003361B8 (pt) 2010-08-13 2022-01-25 Roche Glycart Ag Anticorpo, composição, conjugado de anticorpo,formulação farmacêutica e uso do anticorpo
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування

Also Published As

Publication number Publication date
IL218437A0 (en) 2012-04-30
IL218437A (en) 2017-04-30
EP2483310B1 (en) 2014-08-13
ES2505269T3 (es) 2014-10-09
US20120184718A1 (en) 2012-07-19
US9481730B2 (en) 2016-11-01
CN102574921A (zh) 2012-07-11
PL2483310T3 (pl) 2015-01-30
CY1115639T1 (el) 2017-01-04
SI2483310T1 (sl) 2014-12-31
KR20120056857A (ko) 2012-06-04
AU2010303142A1 (en) 2012-03-15
AU2010303142B2 (en) 2013-05-09
CA2773515C (en) 2015-04-28
PT2483310E (pt) 2014-10-07
JP2013505732A (ja) 2013-02-21
KR101508043B1 (ko) 2015-04-06
WO2011039126A1 (en) 2011-04-07
CA2773515A1 (en) 2011-04-07
HRP20141032T1 (hr) 2015-01-30
DK2483310T3 (da) 2014-09-01
EP2483310A1 (en) 2012-08-08
HK1169132A1 (zh) 2013-01-18
BR112012006326A2 (pt) 2016-11-16
JP5695059B2 (ja) 2015-04-01
CN102574921B (zh) 2016-05-04

Similar Documents

Publication Publication Date Title
MX2012003598A (es) Anticuerpos biespecificos agonistas de receptores de muerte.
MX340558B (es) Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
MX2012007340A (es) Anticuerpos anti/her3 y usos de los mismos.
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
WO2010145792A8 (en) Bispecific antigen binding proteins
SG178886A1 (en) Humanized anti-cdcp1 antibodies
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
MX342034B (es) Proteinas monovalentes que se unen a antigenos.
HK1245802A1 (zh) 多特異性抗體、抗體類似物、組合物和方法
UY33703A (es) Anticuerpos anti-il-23
PH12015502293A1 (en) Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
MY178926A (en) Bispecific anti-vegf/anti-ang-2 antibodies
PH12014501108A1 (en) Anti-il-36r antibodies
NZ702241A (en) Composition comprising two antibodies engineered to have reduced and increased effector function
WO2010115552A8 (en) Bispecific anti-erbb-3/anti-c-met antibodies
MX2013009151A (es) Inmunoterapia mejorada.
PH12014502406A1 (en) Anti-il-23p19 antibodies
WO2012103360A3 (en) Wnt compositions and methods of use thereof
WO2013063613A3 (en) Methods and compositions related to intracellular neutralization by igg
MX2014002996A (es) Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
MX337106B (es) Antagonistas no competitivos de receptores nicotinicos.
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.
AR123070A2 (es) Anticuerpos anti-il-23
TN2013000186A1 (en) Anti-il-23 antibodies

Legal Events

Date Code Title Description
FG Grant or registration